Atenolol in cats with subclinical hypertrophic cardiomyopathy: a double-blind, placebo-controlled, randomized clinical trial of effect on quality of life, activity, and cardiac biomarkers.

摘要: Abstract Objective To compare quality of life (QOL) and activity measures between healthy control cats with subclinical hypertrophic cardiomyopathy (HCM), to evaluate the effect oral atenolol therapy on QOL, activity, circulating biomarkers in HCM. Animals Thirty-two client-owned HCM 27 cats. Methods Owner responses a QOL questionnaire, cardiac biomarker concentrations, accelerometer-based were compared prospectively without HCM, before after treatment (6.25 mg/cat q 12 h) for 6 months. Results Owner-assessed daily living score was lower than controls (p=0.0420). No differences identified any variable. Compared placebo, associated baseline-adjusted mean ± SD heart rate (157 ± 30 vs. 195 ± 20 bpm; p=0.0001) rate-pressure product (22,446 ± 6,237 26,615 ± 4,623 mmHg/min; p=0.0146). A or not demonstrated. Conclusions This study failed identify an owner-assessed these variables at dosage evaluated. These findings do support benefit goal symptom reduction